Want to join the conversation?
$JNJ subsidiary, Janssen Research, said The FDA has granted a fourth Breakthrough Therapy Designation for IMBRUVICA for treating patients with chronic graft-versus-host-disease (cGVHD). FDA also granted the therapy Orphan Drug Designation for cGVHD. IMBRUVICA is jointly developed and commercialized by Janssen Biotech and Pharmacyclics.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?